![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CHUGAI ANNOUNCES CO-DEVELOPMENT AND CO-MARKETING AGREEMENT WITH TAISHO PHARMACEUTICAL FOR THE ANTIRESORPTIVE BISPHOSPHONATE R484
CHUGAI ANNOUNCES CO-DEVELOPMENT AND CO-MARKETING AGREEMENT WITH TAISHO PHARMACEUTICAL FOR THE ANTIRESORPTIVE BISPHOSPHONATE R484
September 13, 2006
Chugai Pharmaceutical Co., Ltd. announced that it has entered into an agreement with Taisho Pharmaceutical Co., Ltd. to co-develop and co-market R484 (generic name: ibandronic acid), a bisphosphonate which Chugai is currently developing in Japan for the treatment of osteoporosis. Under the agreement, Chugai will co-develop the compound with Taisho and co-market it with Taisho Toyama Pharmaceutical Co., Ltd., a subsidiary of Taisho. Chugai will receive an upfront fee and milestone payments from Taisho. JCN Network (http://www.japancorp.net/Article.Asp?Art_ID=13243)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct